CROSSFLIGHT LIMITED
Company number 02111027 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: CROSSFLIGHT LIMITED
Company No. 02111027 | Year Ended 31 March 2025 | Audited Full Accounts
1. Financial Health Score: B+ (Good Health — Minor Symptoms to Monitor)
Crossflight presents as a fundamentally robust patient: a 38-year trading history, a strong balance sheet, consistent profitability, and excellent cash generation. The score is held back from an A-grade by a two-year decline in headline turnover, a 35% fall in pre-tax profit, and an exceptional bad debt event — symptoms that appear transitory rather than chronic, but which warrant monitoring.
2. Key Vital Signs
| Vital Sign | 2025 Reading | 2024 Reading | Interpretation |
|---|---|---|---|
| Turnover | £16.76m | £18.09m | Falling pulse on the surface — but underlying turnover (excl. pass-through DDP revenue) fell only 2.1% |
| Pre-tax Profit | £590,544 | £903,381 | Down 35% — a noticeable temperature, though partly explained by a one-off £135k bad debt |
| EBITDA | £648,594 (3.9% margin) | £1,044,293 (5.8% margin) | Margin compression — the key symptom to watch |
| Net Assets | £4.86m | £4.53m | Strong and growing every year since 2022 (£2.95m → £4.86m, ~18% p.a.) |
| Cash | £1.17m | £1.42m | Slight decline, but deliberately deployed (debt overpayments + two acquisitions) |
| Equity Ratio | ~69% of total assets | ~67% | Excellent — the company owns far more than it owes |
| Liabilities | £1.89m | £1.99m | Cash on hand covers ~62% of all liabilities — exceptional liquidity |
| Dividend Cover | 3.7x (£448k profit vs £120k dividend) | 1.7x | Distributions are prudently scaled to earnings |
| Gearing | Effectively debt-free trajectory | MBO debt (2021) | Group debt on track for full repayment Dec 2025 — 12 months early, with substantial covenant headroom |
| Filing Compliance | All current, none overdue | — | Clean bill of administrative health; audited accounts with going concern confirmation |
3. Diagnosis
Circulatory system (cash flow): Excellent. This is the company's strongest organ. Operating cash flow simultaneously funded accelerated debt repayment, two strategic acquisitions (Adstral Ltd and an express courier business), and a £120k dividend — all without straining liquidity. Bad debts have historically run below 0.03% of turnover, indicating disciplined credit control.
Heart (profitability): Weakened but stable. The 35% profit decline is the most visible symptom. However, the ECG shows this is largely attributable to identifiable, non-recurring events: one major client lost, one client collapse (£140k bad debt — the first material write-off in an otherwise unblemished decade), a full-year property cost, and increased directors' remuneration. Underlying cost control was otherwise tight despite inflation.
Respiratory function (revenue): Slightly laboured. Headline turnover has fallen for two consecutive years (£20.4m → £18.1m → £16.8m). The mitigating diagnosis: much of this reflects the reduction in low-margin DDP pass-through revenue rather than core trading decline (only 2.1%). New business wins hit a nine-year high, and the sales pipeline reportedly accelerated into the new year — early signs of recovery.
Bones (balance sheet): Very strong. Net assets of £4.86m against liabilities of £1.89m, minimal debt, and growing retained earnings. This is a balance sheet built to withstand shocks.
Observations for the chart: Three directors resigned simultaneously in April 2026 alongside new appointments, and PSC records show a shift in control dynamics (name shown to subscribers holding significant influence). This may indicate an ownership succession or restructuring event — not inherently unhealthy, but worth monitoring for continuity. Client concentration remains a structural vulnerability, as the loss of a single major account demonstrably moved results. The e-commerce sector exposure that caused the bad debt has been addressed with a new cash collection mechanism — a sensible prescription, but efficacy is unproven.
4. Recommendations
- Reduce client concentration — the year's results show how one departure and one collapse can cut profits by a third. Broaden the revenue base so no single client can materially wound performance.
- Stress-test the new e-commerce credit controls — verify the revised cash collection framework is operating effectively before scaling further e-commerce fulfilment exposure.
- Embed the acquisitions carefully — two acquisitions in eight months carries integration risk. Track Adstral and the courier acquisition against their investment cases at 6 and 12 months.
- Rebuild the cash buffer post-December 2025 — once the MBO debt is cleared, redirect the freed cash flow to restore cash reserves toward the £1.4m+ historical level before committing to further M&A.
- Watch cost creep — directors' remuneration and the new property were the only rising costs this year; ensure these remain proportionate as margins recover.
- Clarify governance transition — with three simultaneous board departures in April 2026, document succession and decision-making authority clearly for lenders, clients, and suppliers.
- Continue margin discipline — automation and operational leverage investments are the right medicine for the inflationary environment; persist with them.